Reinier Beeuwkes active positions
| Companies | Position | Start | End |
|---|---|---|---|
Braintree Laboratories, Inc.
 Braintree Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Braintree Laboratories, Inc. manufactures pharmaceutical products and drugs. Its products include SUPREP, NuLYTELY and GoLYTELY. The company was founded by Harry Keegan III and Reinier Beeuwkes in 1982 and is headquartered in Braintree, MA. | Director/Board Member | 01/01/1982 | - |
| Founder | 01/01/1982 | - | |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Director/Board Member | 01/01/2002 | - |
Career history of Reinier Beeuwkes
Former positions of Reinier Beeuwkes
| Companies | Position | Start | End |
|---|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Chief Executive Officer | - | 12/09/2014 |
| Chairman | - | 12/09/2014 |
Statistics
International
| United States | 4 |
Operational
| Director/Board Member | 2 |
| Founder | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Braintree Laboratories, Inc.
Braintree Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Braintree Laboratories, Inc. manufactures pharmaceutical products and drugs. Its products include SUPREP, NuLYTELY and GoLYTELY. The company was founded by Harry Keegan III and Reinier Beeuwkes in 1982 and is headquartered in Braintree, MA. | Health Technology |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Stock Market
- Insiders
- Reinier Beeuwkes
- Experience
